Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889

Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research